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Abstract
Approximately 25–60% of patients show specific pharmacological responses to a
particular drug. We call this interindividual variability (IV) response to drugs
affecting their efficacy and the appearance of side effects in individuals. This IV
may be due to multifactorial components such as genetic factors (single nucleotide
polymorphisms, SNPs; and copy number variations, CNV), environmental stimuli,
epigenetic modulation, disease/health conditions, or drug interactions, among
others. Therefore, these factors can influence the response to the drug by modifying
absorption, metabolism, pharmacokinetics (PK), and pharmacodynamics (PD),
causing the loss of treatment efficacy or leading to adverse drug reactions with
negative consequences for patients. The knowledge in pharmacogenetics (study of
pharmacological consequences of single gene mutations) and pharmacogenomics
(study of the influence of many gene or gene patterns in the reponse to drugs),
disciplines that seek to predict how a specific individual responds to the adminis-
tration of a particular drug, has advanced by leaps and bounds thanks to “omics”
technologies. Nonetheless, despite, the development of next-generation sequencing
platforms and the mapping of the human genome have transformed the field of
pharmacogenetics, the translational into clinical practice has been slow. Therefore,
identification of SNPs that could affect the expression of pharmacogenes in order to
make associations with PK and PD will improve our understanding of genetic
effects on drug efficacy and transfer it to the clinic. Type 2 diabetes (T2D) repre-
sents a national public health problem, not only because of the high frequency of
the disease reported worldwide, but also because of the poor adherence to thera-
peutic management, whose causes have not yet been clarified. One of the challenges
in the management of diseases to reach optimal treatment is the complex genetic
background. Hence, the integration of multiple levels of pharmacological informa-
tion, including variation in gene sequence, impact in drug response, and function of
drug targets, could help us to predict sources of interpatient variability in drug
effects, laying the basis for precision therapy. Thus, the present chapter aims to
collect all the available data about genetic variations in pharmacogenes affecting
drug response in T2D and integrate it with their effect on gene expression to
elucidate their impact in pharmacological efficacy.
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1. Introduction
Although there is no consensus in the contribution of genetic component to
drug response, many studies from the 1970s have estimated that could be between
20 and 95% of the variability in drug disposition and effects [1]. The difficulty in
reaching a consensus is because the contribution of environmental and genetic
components to pharmacogenetics cannot be evaluated, through only one
approach, that is, analyzing only one drug or group of drugs, or only a SNP or a
group of SNPs; we have to talk about PK, PD and related outcomes. In this
context, there are a variety of studies focused on PK, or PD, but the convergence
of all these concepts has been difficult, so the translation to the clinical practice
has been challenging. Along with these barriers are additional factors, such as
gene–environment interactions and gene–gene interactions [2]. Moreover, the
different responses among ethnicities are another factor to add to this complex
phenomenon.
The knowledge on which the participation of genetics in response to the action
of drugs in an individual or group of individuals has been generated through
various studies, applying different strategies such as those described below. In this
regard, in past decades, different laboratories in four countries carried out twin
studies with different drugs to determine the contribution of genetic and envi-
ronmental factors to interindividual variations. The results from all studies con-
verged in that PK variation were similar between monozygotic twins and was
preserved within dizygotic twins, and even as similar as the monozygotic twins
[3]. Researchers from these laboratories conclude that genetic factors primarily
controlled interindividual variations in the metabolism of a wide range of drugs
[3–8]. In the field of heritability of antidiabetics drug response, the studies are
scarce, but one classic example is tolbutamide. In this context, an intravenous
administration to 42 nondiabetic subjects, eight of their relatives, and to five sets
of twins, the authors observed a monogenic control of tolbutamide revealed by a
heritability value of 0.995 (this value means that considering a trait with 1.0
heritability, such as a Mendelian trait, the genetic factors have a great or complete
influence in phenotype; in contrast, a trait with 0.0 heritability will not be
influenced by genetic factors) [9]. In a more recent study by Gjesing et al., they
found high heritabilities estimations for acute insulin secretion subsequent to
glucose stimulation (0.88  0.14), for insulin sensitivity (0.26  0.12), disposition
index (0.56  0.14) and disposition index after tolbutamide administration
(0.49  0.14) in 284 non diabetic family members of patients with T2D after an
intravenous injection of tolbutamide [10]. In another study of genome-wide
complex trait analysis in patients in the Genetics of Diabetes Audit and Research
in Tayside Scotland (GoDARTS) study, the heritability of glycaemic response to
metformin varied by response phenotype, with a heritability of 34% (p = 0022)
for the absolute reduction in HbA1c in 2085 individuals in treatment with metfor-
min [11]. Hence, these studies clearly show that the response to different types or
classes of drugs is modulated by the individual’s genetics and can be passed on to
their descendants showing a clearly genetic component.
2. Variability in drug response in T2D
Diabetes has become a health problem (by 2030, the number of individuals with
diabetes is estimated to rise to 578 million and 700 million by 2045) [12]. Approx-
imately, 90–95% of cases of diabetes correspond to T2D. T2D is a chronic metabolic
disease characterized by hyperglycemia, resulting from insulin resistance and
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reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia
and hyperinsulinemia [13].
The great prevalence of T2D impacts both direct and indirect costs. In 2019, the
International Diabetes Federation estimated that total diabetes-related health
spending reached $ 760 billion. By the years 2030 and 2045, spending is forecast to
reach $ 825 billion and $ 845 billion, respectively [12]. Moreover, approximately the
32% of annual costs per diabetic patient is destined to treatment [14]. Furthermore,
approximately 50% of T2D patients have good glycemic control considering HbA1c
< 7%, which means that 50% have poor glycemic control [15]. Besides, as conse-
quence of adverse drug reactions (approximately 20–30%) there is a high preva-
lence of treatment abandonment [16–18] All these facts denote the need for new
drugs or strategies to improve glycemic control. Current treatment to control dia-
betes is aimed at specific key targets in glucose metabolism such as: adipose and
muscle tissue to reduce insulin resistance, or act on the liver to inhibit glucose
production, as well as stimulate the pancreas to release insulin. However, it is
necessary to go beyond lowering glucose levels. In clinical practice it is often
observed that T2D patients who receive identical antidiabetic regimens have signif-
icant variability in drug response, hence interindividual variation may be caused by
numerous factors, such as genetic factors, physical inactivity, hypertension, age,
gender and others [19]. Particularly, the genetic variability of therapy response was
recently shown in several independent studies for the common drugs used for T2D
treatment. Therefore, identification of genetic variants and their impact in drug
response may improve our knowledge in the field, in order to be able of translate it
into clinical practice. This could help in decision making on the therapeutic
approach, reducing the rates of side effects and improving the adherence to treat-
ment. Thus, the present chapter aims to collect all the available data about genetic
variations in pharmacogenes affecting drug response in T2D and integrate them
with their effect on gene expression, and to elucidate their impact on pharmacolog-
ical efficacy.
In order to cover the objective, we compile all the available information about
pharmacogenetics and epigenetics in T2D. We carried out a literature search using
PubMed and Google Scholar. For this purpose, search words used were the follow-
ing: diabetes + pharmacogenetics (826 studies); type 2 diabetes + pharmacogenetics
(421 studies), diabetes + pharmacogenomics (1,184 studies); type 2 diabetes +
pharmacogenomics (456 studies). When we added the words “drug response” the
result was 338 and 267 papers, for pharmacogenomics and pharmacogenetics,
respectively; or when we added the words “personalized medicine” in the search,
we retrieved 152 and 114 papers, for pharmacogenomics and pharmacogenetics,
respectively. Table 1 shows all the studies considered significantly associated with
antidiabetics drug response. Regarding the Epigenetics section, this was covered
with a literature search using the words diabetes + drug response + epigenetics.
Table 2 shows the reports of epigenetics variations that influence drug response in
T2D treatment. All the studies were chosen taking into account glycemic control
and significance.
2.1 Single nucleotide polymorphisms
SNPs, are modifications in the DNA sequence, that implies changes in single
nucleotides, which are the most common variations and the main source of
interindividual diversity [20]. Interindividual variability could be explained in part
by SNPs in genes encoding drug-metabolizing enzymes, transporters, receptors and
molecules involved in drug metabolism. In this context, many SNPs related with the
metabolism of antidiabetic drugs have been described. In the following section we
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Drug group Gene (Encoded
protein)
dbSNP ID Aminoacid change Population Effect References
Biguanides
(Metformin)




rs34130495 Gly401Ser Lower decrease in HbA1c
rs1867351 Ser52Ser Asian Reductions in PPG and ΔHbA1c [134]
rs622342 Intron A > C South Indian Less response to metformin [135]
European Decreased reduction in HbA1c levels [136]
Mexican High ΔHbA1c values [137]
rs36056065 Indel GTAAGTTG European Association with metformin side effects [138]
rs628031 Val408Met Mexican High ΔHbA1c values [137]
Chinese Reduction in ΔHbA1c and ΔFPG [134]
European Association with metformin side effects [138]
rs594709 597 A > G Mexican Increase in HbA1c values [137]
Chinese Increase in FINS decrease in HOMA-IS and in QUICKI [139]
rs145450955 Thr201Met Iranian High HbA1c values [140]
SLC22A2 (OCT2) rs316019 Ala270Ser Chinese Higher incidence of hyperlactacidemia [26, 30, 36]
South Indian Better response










Drug group Gene (Encoded
protein)
dbSNP ID Aminoacid change Population Effect References




rs2289669 g.  130G ! A European Association with reduction in HbA1c levels [29]
SLC47A2 (MATE2) rs12943590 Gly211Val Reduced response [28]
South Indian Better response [30]
rs34399035 Gly393Arg European Lower decrease in HbA1c [133]






Reduction in HbA1c values [34, 35]
Reduction in blood glucose
C11orf65 (MFI) rs11212617 Intron C > A European Association with treatment success [37]






PRPF31 (PRP31) rs254271 Intron T > A /C/G Worse response
STK11 rs2075604 Intron G > T Chinese Better therapeutic efficacy [36]
CAPN10 (CAN10) rs3792269 Arg197Gly European
African
American
Association with less treatment success and with smaller reduction in
HbA1c
[142]






















































Drug group Gene (Encoded
protein)
dbSNP ID Aminoacid change Population Effect References
FMO5 rs7541245 Intron C > A Not provided Association with decreased glycemic response (decrease response to
metformin)
[144]
SLC22A3 (OCT3) rs2076828 C > G European
African
American
Association with reduced response [145]
Sulfonylureas CYP2C9 rs1799853
(*2)
Arg144Cys European Greater response to sulfonylureas [52, 53]
rs105791o
(*3)
Ile359Leu Mexican Association with good glycemic control
ABCC8 rs757110 Ser1369Ala Chinese Association with FPG, 2 h plasma glucose and HbA1c decrease [59, 146]
Association with therapeutic efficacy
rs1799854 Intron C > T European Lower HbA1c concentration [63]
rs1799859 Arg1273Arg
rs1801261 Thr759Thr Chinese Less reduction in FPG and HbA1c levels [147]
KCNJ11 (KCJ11) rs5219 Glu23Lys European
Chinese
Better response [69, 70]
Mexican Lower response [71]
rs5210 UTR G > A Chinese Association with FPG decrease [59]
KCNQ1 rs163184 C > G European Lower FPG response [76]
rs2237892 Intron C > T Chinese Association with treatment success [77]
rs2237895 Intron A > C, T Association with treatment success
TCF7L2 (TF7L2) rs7903146 Intron C > T European Lower effect of gliclazide [148]
Association with therapeutic failure [81, 83]rs12255372 Intron G > T
NOS1AP (CAPON) rs10494366 Intron
G > C/T








Drug group Gene (Encoded
protein)
dbSNP ID Aminoacid change Population Effect References
IRS1 rs1801278 Gly972Arg African Association with increased risk for secondary failure [89, 90]
European
ABCA1 rs9282541 Arg230Cys Mexican Association with decreased response to treatment [91]
Thiazolidinediones PPARG2 (PPARγ2) rs1801282 Pro12Ala Chinese Association with better response [149, 150]
Higher ΔFPG
rs880663 Intron A > G Mexican
American
Association with response to troglitazone [151]
rs4135263 Intron T > C
rs1152003 G > C
rs6806708 G > T
rs13065455 C > A/G
rs13088205 T > G





rs8192678 Gly482Ser Chinese Reduced ΔFPG and ΔFINS [152]
rs2970847 Thr394Thr Reduced ΔPINS
UCP2 rs659366 866 G/A Chinese Smaller attenuated PINS and greater attenuated HbA1c [153]
CYP2C8 rs10509681
(*3)
Lys399Arg European Association with reduced glycemic response [154]

















































Drug group Gene (Encoded
protein)
dbSNP ID Aminoacid change Population Effect References
KCNQ1 rs2237892 Intron C > T Chinese Larger augmentation in Δ2h glucose [77]
rs2237895 Intron
A > C/T
Greater decrement in ΔHbA1c
ADIPOQ (ADPN) rs266729 11377 C > G Attenuated rosiglitazone effect [155]
rs2241766 GLy15Gly Attenuated ΔFINS
Greater decrease in HbA1c and association with pioglitazone
treatment
[156]
rs1501299 SNP + 276 G > T Korean Smaller reductions in FPG and HbA1c [157]
rs182052 10068 G > A Chinese Increased reduction in HbA1c [158]
RETN rs1862513 420 C > G Japanese Correlation with reduction of HbA1c [159]
LEP rs7799039 G-2548A Chinese High differential values of FINS and PINS [160]
TNFA rs1800629 G-308A Lower values of FINS
PTPRD rs17584499 Intron C > T Higher ΔPPG [150]
DPP-4 inhibitors TCF7L2 (TF7L2) rs7903146 Intron C > T European
African
Asian
Lower reduction of HbA1c [161]
KCNJ11 (KCJ11) rs2285676 UTR A > G/T Asian Association with better response [162]
CTRB1/2 rs7202877 T > C/G European Smaller decrease of HbA1c [163]
KCNQ1 rs163184 Intron T > C/G Association with a reduced glycemic response [164]
GLP1R rs3765467 Arg131Gln Korean Association with HbA1c reduction [165–167]
rs6923761 Gly168Ser European
DPP4 rs2909451 Intron C > T Not Provided Association with DPP-4 activity [168]
rs759717 Intron G > C








Drug group Gene (Encoded
protein)
dbSNP ID Aminoacid change Population Effect References
PRKD1 rs57803087 Intron A > G Taiwanese Association with DPP-4 inhibitor response [169]
ABCB1 (MDR1) rs1128503 Gly412Gly Asian Association with response to therapy [170]
CDKAL1 rs7754840 Intron C > G Japanese Association with HbA1c reduction [171]
rs7756992 Intron A > G
GLP-1 receptor
agonists
GLP1R rs10305420 Pro7Leu Chinese [172]
TCF7L2 (TF7L2) rs7903146 Intron C > T Brazilian Association with PINS [173]
rs761386 Intron C > G/T Taiwanese Association with changes in the standard deviation of plasma glucose [174]
SORCS1 (SORC1) rs1416406 A > G/T Chinese Association with FINS [175]
CNR1 rs1049353 Thr453Thr European Association with improvement of insulin resistance [176]
SGLT2 inhibitors UGT1A9 rs72551330 Met33Thr Not Provided Higher AUC (26%) [112, 113]
SLC5A2 (SGLT2) rs9934336 Intron G > A European Association with reduced 30-min plasma glucose [115]
OR: Odd ratio; BG: Blood glucose; FINS: Fasting serum insulin; PINS: Postprandial serum insulin; PPG: Postprandial plasma glucose; HOMA-IS: Insulin sensitivity by homeostasis model assessment; HOMA-
IR: Insulin resistance by homeostasis model assessment; HOMA-BCF: homeostatic index of percentage of β-cell function; FBG: fasting blood glucose; FG: fasting glucose; AUC: Area under the curve. The gray
cells indicate a haplotype associated with metformin intolerance in the study of Dujic et al. in 2015 [132].
Table 1.

















































described the most significant SNPs associated with drug response, specifically
glycemic control, with antidiabetics treatment.
2.1.1 Biguanides (Metformin)
First-line drugs in T2D therapy are biguanides, however, when the patient is not
obese, the sulfonylureas group is usually prescribed and the response to treatment
will be evaluated after 3 months [21]. Guidelines from the American Diabetes
Association/European Association for the Study of Diabetes (ADA/EASD) and the
American Association of Clinical Endocrinologists/American College of Endocri-
nology (AACE/ACE) recommend early initiation of metformin as a first-line drug
for monotherapy and combination therapy for patients with T2D [22]. Approxi-
mately 30% of patients with T2D do not respond to metformin and about 20 to 30%
experience intolerable side effects [23]. There is considerable variability in the
glycemic response and PK characteristics of metformin. In terms of PK, metformin
Drug group Gene /miRNA
(Encoded protein)
CpG site Effect References
Biguanides
(Metformin)



























Sulfonyulureas KCNJ11 (KCJ11) N.R.. 26.2% vs. 27.2% [131]
ABCC8 0% vs. 7.2%
SGLT2
inhibitors




Epigenetics variations that influence T2D treatment.
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is not metabolized, and is excreted unchanged in the urine, with a half-life of
roughly 5 h. In particular, mean plasma concentrations of metformin fluctuate
between 0.4 and 1.3 mg/L at a dose of 1,000 mg twice daily [24].
The disposition of metformin includes elimination and tissue distribution, which
in turn involves organic transporters (OCTs) and multidrug and toxin extrusion
proteins (MATEs); both may contribute to the wide variation in metformin PK.
Metformin response variability is important, in fact >30% of patients receiving
metformin are classified as poor responders [23]. This drug is a polar molecule
largely eliminated by the kidney without undergoing hepatic metabolization. The
processes of uptake and secretion of metformin are highly dependent on membrane
transporters, among which are solute carrier family 22A members 1 and 2
(SLC22A1/OCT1 and SLC22A2/OCT2, respectively), multidrug and toxin extrusion
proteins MATE1 (SLC47A1) and MATE2 (SLC47A2) and the plasma membrane
monoamine transporter PMAT (SLC29A4/hENT4). Therefore, impacting variants
in any of these transporters may have an influence in metformin efficacy and
adverse effects (Table 1). In this context, the most studied genes are SLC22A1/
OCT1, SLC22A2/OCT2, SLC47A1/MATE1 and SLC47A2/MATE2. Genetic variants
in SLC22A1/OCT1 are responsible for the adverse gastrointestinal effects experi-
enced by many patients with T2D diabetes who use metformin. Dujic et al. found
that 47% of participants with T2D, incident users of metformin, experienced gas-
trointestinal adverse effects. In the study the number of SLC22A1/OCT1 reduced-
function alleles was highly correlated with over two-fold risk of gastrointestinal side
effect development [25]. Consequently, the gastrointestinal adverse effects and in
some cases intolerance to metformin could lead to treatment abandonment. In this
same gene other variants associated to metformin response have been reported. As
it can be seen in Table 1, most of the reported variants are related to a decrease in
the effect of metformin, reflected in the less reduction in HbA1c levels (high
concentration of HbA1c). In contrast variant rs316019 in SLC22A2/OCT2 is associ-
ated with lactic acidosis and better response to metformin, due to the evidence that
this variant is related to a reduced level of metformin clearance [26, 27]. Therefore,
patients with these variants may benefit receiving alternative therapy instead
metformin.
The studies that evaluated the role of SLC47A1/MATE1 and SLC47A2/MATE2
SNPs in PK and PD in patients receiving metformin revealed that promoter variants
in MATE1 (g.-66 T ! C, rs2252281; g.-130G ! A, rs2289669) are associated with a
greater response to the drug in T2D patients [28, 29]. Interestingly, it is also
reported that the MATE1 variant affects the PD but not the PK of metformin, a very
important finding that reveals that the distribution of drugs occurs in response to
the organ-specific location of the various transporters [28]. Most studies have
associated variants in SLC47A2/MATE2 with contradictory effects. Concerning
rs12943590, it was related to a reduced response in European populations and a
better metformin response in South Indian populations; whilst rs34399035 was
associated with a reduced response to metformin in European populations [28, 30].
It is important to mention that the studies were carried out in different populations,
and that investigations in other ethnicities had not found associations between these
variants and metformin response [31, 32]. In a recent meta-analysis by Dujic et al.
there was no association between rs12943590 and glycemic response [33]. None-
theless, it is important to note that SNP-drug interactions and SNP-SNP interactions
cannot be ruled out, since the presence of other SNPs also modulate the response to
drugs and are different in each individual, thus, genotyping of these SNPs should be
considered if it is desired apply personalized medicine in diseases such as T2D [28].
Other SNPs in candidate genes such as SLC2A2/GLUT2 (solute carrier family 2/
Glucose transporter 2) have been associated with reduction in HbA1c or treatment
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success, together with rs11212617 in C11orf65 (MFI, inhibitor of mitochondrial
fission), in rs2162145 CPA6 (encoded protein CBPA6, this peptidase may convert
inactive angiotensin I into the biologically active angiotensin II) and rs2162145 in
STK11 (serine/threonine-protein kinase involved in cell metabolism) [34–38]. In
contrast, variants in genes PRPF31 (PRP31), CAPN10 (CAN10), SP1, FMO5 and
SLC22A3 (OCT3) are related to reduced response to metformin. Nonetheless, these
associations have not been replicated in other studies or populations.
2.1.2 Sulfonylureas
Sulfonylureas are a class of oral antidiabetic agents widely used for the manage-
ment of T2D [39]. They are chosen in the first line of treatment if the patient does
not present with obesity or with insulin resistance or if there is intolerance or
contraindication to metformin. Also, they are used in the second line in combina-
tion with other oral hypoglycemic agents, such as metformin [40]. According to the
2003–2016 National Health and Nutrition Examination Survey (NHANES), sulfo-
nylurea monotherapy decreased from 33–8%, nonetheless, the combination with
insulin or metformin was used in 50% of patients in the mentioned period [41].
Patients with a short duration of diabetes with residual beta cell function (high C-
peptide levels) are likely to be most responsive to sulfonylurea therapy [42]. The
mechanism of action of sulfonylureas consists of promoting insulin secretion via
binding to sulfonylurea receptor 1 (SUR1), an element of the ATP-sensitive K+
(KATP) channel. The link between sulfonylurea and SUR1 inhibits the K-ATP
channel, depolarizing the β cells, increasing intracellular Ca2+, and consequently
insulin granule exocytosis [43]. The rise of insulin levels regulates postprandial
glycemia, stimulating peripheral glucose utilization [44]. Despite, sulfonylureas
have a relatively short half-lifes (3 to 5 hours); they can cause hypoglycemia, which
affects the quality of life and adherence to therapy in patients with T2D [45]. Two
studies have reported hypoglycemia had occurred in 16–39% of patients treated
with sulfonylureas [46, 47]. As a consequence, it has been estimated that 10–20% of
individuals treated with sulfonylureas do not attain adequate glycemic control and
5–10% initially responding to sulfonylurea subsequently lose the ability to maintain
normal glycemic level [48].
The most commonly used sulfonylureas, including the second-generation:
glyburide, glipizide, and glimepiride are mainly metabolized through the cyto-
chrome P450 (CYP) 2C9 enzyme. CYP2C9 belongs to the cytochrome P450 gene
family and is the enzyme most abundantly expressed in liver. Indeed, CYP2C9
accounts for approximately 20% of total hepatic P450 protein, based on mass
spectrometry quantitation [49]. It contributes to the metabolism of approximately
15% of all drugs that are subject to P450-catalyzed biotransformation, and it is
responsible for >25% of metabolic clearance of oral hypoglycemic agents, such as
chlorpropamide, glibenclamide, gliclazide, glimepiride, nateglinide and tolbuta-
mide [50, 51]. Although CYP2C9 is highly polymorphic, however, only two poly-
morphisms have shown impact in enzyme expression and function, both allelic
variants CYP2C9*2 (Arg144Cys, rs1799853) and CYP2C9*3 (Ile359Leu, rs1057910),
encode proteins with less enzymatic activity for the metabolism of several sub-
strates compared with the wild-type allele CYP2C9*1 (Arg144/Ile359). CYP2C9*2
and CYP2C9*3 are generally associated with more than 80% reduction in CYP2C9-
mediated intrinsic clearance, while the effect of CYP2C9*2 is generally slightly
smaller and varies considerably, depending on the substrate [51]. In both cases
patients present more drug event reactions. Some studies have shown that CYP2C9
loss-of function alleles CYP2C9*2/*3 are associated with higher sulfonylurea levels
and greater response to sulfonylureas. In the Go-DARTS study, patients with two
copies of a loss-of-function allele were 3.4 times more probable to reach good
12
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glycemic control compared with patients with two wild-type CYP2C9 alleles,
corresponding with a 0.5% greater reduction in HbA1c [52, 53]. In several pharma-
cokinetic studies the two variants rs1799853 and rs1057910 in CYP2C9 have been
associated with hypoglycemic events, suggesting identification of these variants as a
tool to predict adverse effects of these drugs in the patients with T2D [54].
Polymorphisms in KCNJ11, ABCC8, NOS1AP, TCF7L2, CYP2C8, KCNQ1, and
IRS1 genes have been associated with altered therapeutic response to sulfonylureas,
which will be described below [55]. ABCC8 and KCNJ11 encode K-ATP channel
proteins SUR1 and Kir6.2, respectively, both form the K-ATP channel, which con-
trols glucose-dependent insulin secretion in pancreatic β-cells [56, 57]. It has been
reported that 50% of cases of neonatal diabetes are caused by mutations in KNJ11 or
ABCC8 (SUR1) [58]. Therefore, genetic variants in ABCC8 and KCNJ11 genes could
influence K-ATP channel function of beta cells, leading to changes in depolarization
of the cell membrane and impact insulin secretion. Most studied SNPs in the ABCC8
gene include rs757110 (Ser1369Ala), rs1799854 (intronic variant) and rs1799859
(Arg1273Arg). Feng et al. demonstrated the association of the Ser1369Ala variant in
the ABCC8 gene with fasting plasma glucose test (FPG) and two-hour plasma
glucose after oral glucose tolerance test decreases after 8 weeks of gliclazide ther-
apy. Additionally, the authors found a nominal association of the variant with levels
of HbA1c, suggesting a role of this SNP on antidiabetic efficacy of gliclazides [59].
Several authors have attempted to associate this variant with insulin secretion;
however, the findings have been contradictory. A study in the Diabetes Prevention
Program population that includes Caucasian, African Americans, Hispanic Ameri-
cans, American Indians and Asian Americans, found an association with a signifi-
cantly lower insulin index, nevertheless, other studies failed to replicate this
association [60–62]. Despite these data, it is interesting to mention that variant
Ser1369Ala has been related with progression to diabetes [60]. Nikolac et al., found
that rs1799854 and rs1799859 in the ABCC8 gene were associated with sulfonylurea
efficacy in Caucasians, evidenced by significantly lower HbA1c concentrations in
carriers compared with noncarriers [63].
As mentioned above, the KCNJ11 gene encodes the Kir6.2 subunit; four pore
forming subunits assemble with four regulatory subunits of SUR1 to form the K-
ATP channel of the β-cell [64]. Two SNPs have been associated with sulfonylureas
response, rs5219 and rs5210. The rs5219 (Lys23Glu, p.E23K) A allele plays an
important role in insulin secretion through reduction of ATP sensitivity of the K-
ATP channel and suppression of insulin secretion. Previous studies, have demon-
strated that carriers of a common variant, E23K, with normal glucose tolerance
showed up to 40% reduction in glucose-stimulated insulin secretion [65, 66]. How-
ever, the mechanism of action of this locus in the insulin secretion pathway is still
not completely understood. Although early observations have reported that E23K
carriers exhibit higher predisposition to secondary failure when treated with sulfo-
nylureas, other investigations have associated this variant with a better response to
sulfonylureas [67–70]. Additionally, some studies have suggested that the presence
of the E23K variant is related to the severity of hypoglycemia in patients with
sulfonylureas therapy or with lower response [68, 71]. Regarding rs5210, it has been
reported that the G allele acts as a potential target for miR-1910, which is implicated
in T2D; however, the mechanism of action of this miRNA in the development of
T2D is unknown [72]. Moreover, variant rs5210, has been associated with gliclazide
response, revealed by decreased levels of FPG test in carriers of this SNP [59].
The KCNQ1 gene belongs to a large family of voltage-gated K+ channels [73].
Although KCNQ1 is mainly expressed in the tissues or cells in the heart, it is also
expressed in other tissues or organs such as pancreas islets [74]. Blockading the
channels with KCNQ1 inhibitors, might stimulate secretion of insulin in pancreas,
suggesting the association of KCNQ1 with the regulation of insulin secretion,
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specifically with reduced insulin secretion [75]. The intronic SNPs rs2237892 and
rs2237895 were shown to increase gliclazide efficacy, whereas the intronic variant
rs163184, was reported to lower-sulfonylureas effects on FPG levels [76, 77].
The transcription-factor-7-like-2 (TCF7L2) gene encodes the transcription fac-
tor 7 like-2 [78]. TCF7L2 can act through GLP-1 protein (Glucagon Like Peptide 1),
which plays a central role in glucose homeostasis and is involved in the regulation of
insulin secretion [79]. Several studies have suggested that TCF7L2 stimulates the
proliferation of β-cells in the pancreas and facilitate the production of GLP-1 in
intestinal cells. In this context, it is postulated that the SNP rs7903146 could
decrease the expression levels of TCF7L2 in the pancreas and lead to lower secretion
of insulin due to the decreased levels of GLP1. However, the association between
TCF7L2 and T2D is more complex and is not limited to the decrease in GLP1, but
also to alterations in other processes regulated by TCF7L2 such as the differentiation
of pancreatic beta cells, in the normal metabolism of cholesterol and in the produc-
tion of other incretins [80]. Pearson et al. determined the association of two genetic
variants rs1225372 and rs7903146 in TCF7L2 with the treatment success of sulfo-
nylurea therapy in T2D patients. It was shown that 12% of the diabetic population
are homozygous carriers of SNP rs1225372 and were twice as unlikely to achieve
good glycemic control within 1 year of treatment initiation compared to 42% of the
population with wild type [81]. These findings were replicated in Indian and Euro-
pean populations among others [82, 83]. Therefore, carriers of these variants are at
high risk of therapy failure with sulfonylureas.
The rest of SNPs that were associated with decreased response to sulfonylurea
treatment and are found in the following genes: nitric oxide synthase 1 adaptor
protein (NOS1AP), insulin receptor substrate 1 (IRS-1) and ATP binding cassette
subfamily A member 1 (ABCA1). NOS1AP binds to neuronal nitric oxide synthase
(nNOS). This enzyme plays a role in the electrical current of the heart and in insulin
release from pancreatic β cells [84, 85]. Some polymorphisms in the NOS1AP gene
have been described as predictive markers of cardiovascular mortality in diabetics
treated with sulfonylureas. In patients with the rs10494366 TG/GG genotypes,
glibenclamide is less effective in reducing glucose levels and mortality rates com-
pared with the wild type TT genotype. By contrast, mortality risk was lower in
tolbutamide and glimepiride users who carried a G allele compared with the T/T
genotype [86]. Of note, no genotype differences in mortality were observed in
metformin or insulin users. The mechanisms through which this polymorphism
influenced mortality risk and the reason why this association differed based on the
type of sulfonylurea used are unclear. Moreover, it was shown that in users of
glibenclamide the TG and GG genotypes were associated with an increased risk of
mortality; in tolbutamide and glimepiride users, the TG or GG genotypes were
associated with a reduced risk of mortality [87]. Conversely, in a Korean study no
significance was found between rs10494366 in the NOS1AP gene and response on
glimepiride treatment [88].
Regarding rs1801278 in the ISR-1 gene, this variant has been associated with
increased risk for secondary failure in African an European populations [89, 90].
In case of rs9282541, T2D patients carriers of variant needed a higher dose of
glyburide in order to achieve the same glucose lowering effect that persons with the
wild type variant [91].
2.1.3 Thiazolidinediones
Thiazolidinediones (TZDs) are pharmacologic agents that specifically treat
insulin resistance. TZDs are effective at lowering HbA1c by 1–1.25% on average
[92]. Despite durability in action, TZDs show weight gain which has limited their
clinical utility [93, 94]. For every 1% reduction in HbA1c, an estimated 2–3% weight
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gain is reported [95]. TZDs are transported into the liver by OATP1B1 (encoded by
SLCO1B1 gene) and metabolized by CYP450 2C8 enzyme (encoded by CYP2C8
gene) [96, 97]. The most studied variant allele in the CYP2C8 gene is CYP2C8*3,
which comprises two linked polymorphisms at codon 139 and codon 399
(Arg139Lys; Lys399Arg) [98].
TZDs decrease insulin resistance directly through activation of peroxisome
proliferator-activated receptors-γ (PPARγ) receptors, which facilitate differentia-
tion of mesenchymal stem cells into adipocytes, promote lipogenesis in peripheral
adipocytes, decrease hepatic and peripheral triglycerides, decrease activity of vis-
ceral adipocytes, and increase adiponectin. These primary effects of TZDs markedly
ameliorate insulin resistance and decrease insulin requirements [99, 100]. Individ-
uals differ in drug response, and  20–30% of diabetic patients fail to respond to
thiazolidinediones [101]. To date, numerous case–control studies have been
conducted to identify the possible relationship between PPARG gene polymor-
phisms with the risk of T2D in various ethnic populations [102]. The most common
variant is located at exon-2 of PPARG, rs1801282, and consists of a non-synonym
change Pro12Ala. This substitution leads to a change in the structure of PPARγ
protein, which in turn decreases the binding effect of target genes, and reducing
transcriptional activity [103]. PPARγ is also the target of antidiabetic TZD drugs,
which have a unique and powerful insulin-sensitizing effect [119].
2.1.4 DPP-4 inhibitors/GLP-1 receptor agonists
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are enzyme inhibitors that
inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of the DPP-4
enzyme prolongs and enhances the activity of incretins which play an important
role in insulin secretion and blood glucose regulation [104]. DPP-4 is a 766 amino
acid transmembrane glycoprotein, which is also known as adenosine deaminase or
CD26, is a ubiquitously expressed glycoprotein of 110 kDa, which was first charac-
terized by Hopsu-Havu and Glenner [105].
The DPP4 gene encodes a serine aminopeptidase enzyme, which inactivates
GLP-1, GIP and other proteins via dipeptide cleavage of the N-terminal amino acid.
Other DPP-4 substrates include peptides containing proline or alanine, such as
growth factors, chemokines, neuropeptides, and vasoactive peptides [106].
Inhibitors of DPP-4 reversibly inhibit the hydrolysis of endogenous incretins,
which increases plasma levels of GIP and GLP- 1, producing an increase in insulin
response and a decrease in glucagon secretion. Therefore, the increase in the con-
centration of GLP-1 in plasma is the pharmacological effect of DPP-4 inhibitors,
which increases insulin synthesis in β cells of the pancreas, stimulates the growth of
these cells and prevents apoptosis [107]. Hence, DPP4 inhibition leads to greater
exposure to incretins and therefore prolongs the half-life of insulin action. Because
of this, DPP4 became a major target for the treatment of T2D [108].
However, it has recently been reported that some patients taking DPP-4 inhibi-
tors are at increased risk of heart failure. It has been suggested that DPP-4 poly-
morphisms could potentially lead to a change in gene expression in renal cells in
patients with T2D; these changes would be related to the renin-angiotensin-aldo-
sterone system causing cardio-renal damage or myocardial hypertrophy, however
further studies are needed to clarified the impact of these polymorphisms in DPP-4
inhibitors response [109].
2.1.5 SGLT-2 inhibitors
Sodium-glucose cotransporter inhibitors are adjunctive medications in the
treatment of T2D. These drugs decrease HbA1c concentrations in diabetic patients,
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with few adverse effects seen to date. In a healthy adult, the kidneys filter approx-
imately 180 g of glucose per day, this is almost entirely reabsorbed into the circula-
tion and less than 1% of glucose is excreted in the urine filtered. This reabsorption is
possible thanks to the action of a family of transmembrane proteins called sodium-
glucose cotransporters (SGLT, sodium glucose co-transporter) [110]. So far, seven
types of sodium-glucose transporters have been identified. Particularly, type 2
(SGLT2) is responsible for glucose renal reabsorption; and is mainly found in the
epithelial cells of the proximal convoluted tubule.
Glycosuria, which was initially observed as an etiopathogenic component of
some renal and urinary complications in patients with T2D, has been proposed as a
means to lower glucose concentrations through the pharmacological use of SGLT2
inhibitors [111]. Some SGLT-2 inhibitors can be glucuronidated by UGT enzymes
(UDP-glucuronosyltransferase), thereby polymorphisms like UGT1A9*3 allele
(rs72551330), in the genes encoding these drug-metabolizing enzymes could poten-
tially influence its response. Despite, higher values of area under the curve (AUC)
of canaglifozina in carriers if UGT1A9*3, the studies have not found clinical impli-
cations [112, 113]. Recently Zimdahl et al. found that common genetic variants in
the SLC5A2 gene do not affect diabetes-related metabolic traits and they do not
have a clinically relevant impact on response to treatment with the SGLT2 inhibitor
empagliflozin [114]. Nonetheless, a study in a Caucasian population showed that
rs9934336 carriers presented increased 30-min glucose concentrations after oral
glucose tolerance test [115]. Studies on these drugs are few, because SGLT2 inhibi-
tors are relatively recent. Thus, the efficacy and safety evaluation of these drugs in
various clinical settings has not yet been fully established.
2.2 Epigenetics
Despite, the major contribution in drug response can be attributed to genetic
components, common genetic polymorphisms explain only less than half of this
genetically encoded variability, thus it is important to address other factors of drug
response, such as pharmacoepigenomics [116].
Pharmacoepigenomics combines the analysis of genetic variations and epige-
netic modifications in an effort to advance personalized medicine [117]. Epigenetic
modification refers to processes that modify DNA or chromatin structure in a
manner that alters the level of expression of genes but not the DNA sequence itself.
Chemical processes that fall into the realm of epigenetics include DNA methylation
and post-translational modifications of histones such as the addition of methyl,
phosphate, and acetyl groups. These modifications influence the overall
chromatin structure and the availability of gene regulatory regions to transcription
machinery [118].
On the other hand, regulatory processes involve molecules such as miRNas.
Although miRNAs do not directly interact with DNA, they inhibit mRNA transla-
tion, therefore it is considered as having epigenetic effects [119].
Specific genes can be expressed or silenced depending on specific stimulators,
such as hormone levels, dietary components or drug exposure, and can also accom-
modate gene-expression changes in response to gene–environment interactions
[120]. Although, the cellular machinery responsible for the secretion of miRNA is
not fully understood yet, it is recognized that miRNAs are packaged into
microvesicles, exosomes, lipid drops and apoptotic bodies by a broad range of cell
types and can be found in various types of body fluids, such as serum, plasma, and
urine [121]. The miRNAs participate as negative regulators in post-transcriptional
processes inhibiting mRNA translation or degrading the mRNA via the seed
sequence region at the 50 end of the miRNA, which allows the binding to its
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3-´untranslated region (3 -UTR) of mRNA. miRNAs are estimated to affect
approximately 30% of the process of protein coding genes [122]. A single miRNA is
responsible for the expression of hundreds of proteins, and a protein-coding gene
can be modulated by more than one miRNA, this is therefore a highly complex
mechanism, but its results largely contribute to inter-individual variability in
response to drugs. Although the study of miRNAs has focused on their involvement
in the genesis of some complex diseases [123, 124] there is some evidence about
their participation in the response to treatment in T2D. Interestingly the treatment
with dapagliflozin (an inhibitor of sodium-glucose co-transporter 2, SGLT2), but
not with hydrochlorothiazide (useful in treating high blood pressure), significantly
up-regulated miR30e-5p and downregulated miR199a-3p (P < 0.05). These
miRNAs are involved in the pathophysiology of heart failure and suggest a
cardioprotective effect of SGLT2 inhibitor response [110].
Metformin can also interfere with the levels of miRNAs in the blood, which
results in a change in the expression of the genes that are controlled by these. Ortega
et al. have shown that increasing the dose of metformin modifies the levels of
circulating miRNAs (started at a 425 mg/day and increased progressively during the
first week to reach 1,700 mg/day), increased miR-192 (49.5%; P = 0.022) and
decreased miR-140-5p (15.8%; P = 0.004), and miR-222 (47.2%; P = 0.03), in
parallel to decreased fasting glucose and HbA1c. Revealing the response of circulat-
ing miRNAs to metformin therapy [125].
The information generated on miRNAs and their molecular actions place these
molecules as innovative applications in the industry. Among the most promising
prospects is the use of miRNA in medical therapy. Future studies of miRNAs that
allow the generation of knowledge about their probable role in the modulation of
pharmacogene expression will undoubtedly contribute to personalizing the treat-
ment of T2D. miRNA-based therapies offer advantages over other nucleic acid
therapies, because miRNAs are efficient silencers and, in contrast to plasmid DNA
or synthetic oligonucleotides, miRNAs are naturally found in the bloodstream. As
they target multiple mRNAs, the resulting synergistic effects could be positive for
therapy, however, there are still multiple aspects that must be addressed before
application to clinical trials in various human pathologies, among them, to identify
the best miRNA candidates of miRNA targets for each disease type, the design of
more efficient vehicles for the targeted delivery of oligonucleotides to specific
organs, as well as avoiding potential toxicities and off-target effects. Low toxicity
and good tolerance in patients treated with antagomiR a 15-nucleotide locked
nucleic acid–modified antisense oligonucleotide whose action is sequestering
mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function
avoiding the stability and propagation of hepatitis C virus (HCV), supporting the
beneficial role of miRNAs in therapy [126]. miRNAs are naturally endogenous
regulators of cell processes that are often dysregulated in diabetes restoration of
any given miRNA function to normal levels will be the ultimate therapeutic goal.
Several miRNAs appear to affect the function of the differentiated state of the
pancreatic β-cell, while miRNAs in skeletal muscle, the liver, and adipose tissue
constitute sets of different miRNAs, which is why the choice of the best
molecules to treat this disease becomes very complex. Several challenges will need
to be overcome in the field of pharmacotherapy with miRNA in the control of
diabetes, but they will undoubtedly contribute to personalizing the treatment of
this disease.
It has been suggested that epigenomics may act synergistically with pharmaco-
genomics towards optimization of drug therapy [127]. In addition, epigenomic
somatic alterations represent an emerging class of biomarkers that hold promise for
personalized therapy particularly to overcome drug resistance [128].
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Regarding methylation, García-Calzón et al. evaluated the potential blood epi-
genetic markers associated with metformin glycemic and intolerance response.
They analyzed DNA methylation in blood from newly diagnosed patients with T2D
after 1.5 years of metformin treatment. According to the authors, the methylation
risk scores explain 68–73% of the variation in glycemic response to metformin. In
addition, the methylation risk scores explain 50–51% of the variation in metformin
tolerance. In the same study, the researchers also assessed whether any of 26 SNPs
previously associated with metformin response were associated with DNA methyl-
ation of any of the identified epigenetic markers. They identified one significant
association between a SNP in SCL22A1 (rs628031) and DNA methylation of
cg05151280 (P = 0.001, q = 0.028). The A/A genotype carriers had lower methyla-
tion (83.6  2.3%) compared to carriers of the G/G (85.3  1.9%, P = 0.002) and
G/A (85  1.8%, P = 0.006) genotypes in 132 participants from the discovery and
replication cohorts. Lower methylation of this CpG site was associated with a better
glycemic response to metformin (Table 2) [129]. In previous work from the same
group, they assessed the DNA methylation in OCT1 encoded by SLC22A1, OCT3
encoded by SLC22A3, and MATE1 encoded by SLC47A1 liver biopsies from gastric
bypass surgery. Lower promoter DNA methylation of SLC22A1, SLC22A3, and
SLC47A1 were found in diabetic subjects receiving metformin. These findings sug-
gest that metformin decreases DNA methylation of metformin transporter genes in
the human liver, in contrast with the higher methylation levels in these genes
associated with hyperglycemia and obesity. These findings show how a drug is
capable of modulating gene expression however, the presence of genetic variants in
these genes would be interfering with the methylation process with unexpected
results [130].
Methylation in KCNJ11 and ABCC8 gene promoters in T2D patients receiving
sulfonylurea therapy have been assessed by Karaglani et al., their results show
that epigenetic changes such as methylation influence interindividual variability
in treatment with sulfonylureas. They considered hypoglycemia as an outcome
of the treatment. KCNJ11 methylation was detected in 21.6% of hypoglycemic
individuals and in 27.7% of non-hypoglycemic patients (P = 0.353) in this
study, while ABCC8 methylation in 7.2% of non-hypoglycemic and none of
the hypoglycemic patients (P = 0.012). These findings suggest that ABCC8
methylation is associated with hypoglycemic events in sulfonylurea-treated T2D
patients [131].
3. Conclusions
The interindividual variability in the response to a drug is the consequence of
various factors, including pharmacokinetic causes: absorption, distribution,
metabolization and excretion of the drug that affects the intensity and duration of
the response, or to pharmacodynamic causes in drug-receptor interaction. Each of
these PK and PD factors is different in each individual due to genetic, environmen-
tal or pathological determinants, and also depends on the severity or intensity of the
disease to be treated.
One of the main obstacles to transferring findings from pharmacogenetics to the
clinic is the impact of ethnicity on genetic variation. The highly significant associa-
tions between SNPs and the response modulated by pharmacogenetics can differ
considerably between populations, which has a direct impact on drug use and
dosage decisions. It is necessary then that the studies to evaluate pharmacological
efficacy and pharmacogenetics, have uniformity in research designs, dosage
regimens, study populations, and analytical methods.
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The epidemic of T2D has forced the use of drugs that aim at glycemic control
and avoid secondary complications that cause very high medical costs and decrease
the quality of life of patients. However, it has been observed that even though many
patients carefully follow medical guidelines, the glycemic control so desired is not
achieved. Thus, with the advent of pharmacogenomics, various studies are carried
out to achieve personalized medicine in this field having an impact on a better
quality of life and also reducing the costs of treatment of this disease by the Health
services.
In this review, the main drugs used for the treatment of T2D were analyzed and
the implications that the various SNPs have on their target genes, which will affect
their pharmacological response. All this opens the way for us to apply these genomic
findings in daily clinical practice, in search of personalized medicine that impacts
adequate glycemic control in patients with T2D in search of a better quality of life.
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